San Francisco, California, USA
London, United Kingdom
A satellite event of the 2013 Open Knowledge Conference. Please quickly register above so we may give WHO security a list of attendees and can plan ahead for seating etc. If you can, please provide name and affiliation.
Location: WHO HQ in Geneva
Please go directly to the WHO-UNAIDS building, opposite the main WHO HQ building. We are in meeting room D46031 (take lift 33/34 to go to the 4th floor). If you arrive before 9 we will go up as a group. If you arrive after 9, please ask reception for help.
Part 1 - A Summary of Current Moves Towards Openness in Drug Discovery and Development
The session will be opened by some general remarks from John Reeder, TDR Director.
A scope-out of the session will then be provided by Dr Mat Todd, University of Sydney.
Speakers have 10 minutes (Powerpoint OK) each to outline their organization's approach towards more open drug discovery.
Speaker 1: MMV (Marion Colombani)
Speaker 2: WHO/TDR (Robert Terry)
Speaker 3: DNDi (Charles Mowbray)
Speaker 4: GSK Tres Cantos (Lluis Ballell)
Speaker 5: Structural Genomics Consortium (Chas Bountra)
Speaker 6: WIPO (Thomas Bombelles)
Part 2 - Discussion
Led by panel, to include audience.
Discussion will initially centre on the above presentations, but will focus specifically on the following three questions:
Q1: Can a public domain drug candidate be developed as a medicine that will reach patients?
Q2: Does patent protection add value/incentive to the research process that outweighs the limits placed on collaboration?
Q3: Can major diseases be tackled using money that originates only from the public/NGO sector?
Q4: Will prizes stimulate research activity in drug discovery?
Other questions of interest:
a) Are there concrete examples of how the release of open data has benefitted the releaser?
b) Has there been significant progress on defining pre-competitive collaboration, and concrete examples of outcomes that are now being employed? Are the outcomes proprietary, or open?
c) If NGOs fund research at pharma companies, should the data be made openly available via the contract?
This meeting is being supported by WHO/TDR.
(We are working to record this session - audio and hopefully video. Participants will be advised of these arrangements on the day)
When & Where
Matthew H Todd
Mat's at the School of Chemistry, The University of Sydney